KEROS THERAPEUTICS, INC. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/e63e46fd-e44b-404e-9b31-a5d31709dd44/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $67.6M | 2025-01-01 – 2025-12-31 | evidence 0001664710-26-000018 |
| FY 2024 | $-210.8M | 2024-01-01 – 2024-12-31 | evidence 0001664710-25-000018 |
| FY 2023 | $-169.9M | 2023-01-01 – 2023-12-31 | evidence 0001664710-24-000017 |
| FY 2022 | $-114.8M | 2022-01-01 – 2022-12-31 | evidence 0001664710-23-000021 |
| FY 2021 | $-56.4M | 2021-01-01 – 2021-12-31 | evidence 0001664710-22-000011 |
| FY 2020 | $-46.7M | 2020-01-01 – 2020-12-31 | evidence 0001664710-21-000018 |
| FY 2019 | $-10.6M | 2019-01-01 – 2019-12-31 | evidence 0001664710-21-000018 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).